TheraVac Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

TheraVac Biologics is a preclinical-stage biotech leveraging a proprietary VLP platform to develop active immunotherapies for neurodegenerative and chronic inflammatory diseases. Founded in 2016 and based in San Diego, the company's pipeline is led by TV-301 for Alzheimer's disease and TV-202 for frontotemporal dementia, both in preclinical development. The platform aims to generate strong, targeted immune responses without traditional adjuvants, potentially offering safer and more effective treatments for conditions with high unmet medical need. The company is privately held and appears to be pre-revenue, advancing its programs through academic collaborations.

Alzheimer's DiseaseFrontotemporal DementiaMultiple SclerosisTraumatic Brain InjuryNeurodegenerative Diseases

Technology Platform

Virus-Like Particle (VLP) platform for multivalent display of immunogenic peptides to elicit strong, adjuvant-free immune responses against target proteins.

Opportunities

The aging global population creates a massive and growing addressable market for neurodegenerative disease treatments, with Alzheimer's being the largest segment.

The company's VLP platform offers a potential advantage in safety (adjuvant-free) and cost of goods compared to chronic infusion therapies, and its technology could be applied to multiple diseases driven by protein aggregation or inflammation.

Risk Factors

High scientific risk in translating preclinical vaccine data to clinical efficacy in complex neurodegenerative diseases.

Intense competition from large pharma and well-funded biotechs in the Alzheimer's space.

Financial risk associated with being a private, preclinical company reliant on raising capital to reach clinical milestones.

Competitive Landscape

TheraVac competes in the crowded neurodegenerative disease space, particularly against companies developing immunotherapies for Alzheimer's (e.g., Biogen/Eisai, Lilly, Roche, Prothena). Its differentiation lies in its active vaccine (VLP) approach, which contrasts with the dominant passive antibody therapies. It also faces competition from other active immunotherapy developers and companies targeting neuroinflammation (e.g., via NLRP3 inhibition).

More companies in Biologics / Biosimilars →More companies in United States →